Finanzas de Immunovant Inc (IMVT)IMVTImmunovant Inc

Evaluating the bottom line, Immunovant, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -80.10%, provide a clear picture of how effectively IMVT converts its operational activities into shareholder value.

In the context of the broader market, IMVT competes directly with industry leaders such as KOD and CGON. With a market capitalization of $5.52B, it holds a significant position in the sector. When comparing efficiency, IMVT's gross margin of N/A stands against KOD's N/A and CGON's -239.24%. Such benchmarking helps identify whether Immunovant, Inc. is trading at a premium or discount relative to its financial performance.

Immunovant's financial performance shows significant net losses, with net income to common shareholders reaching -147.86 million USD in Q4 2026. The company's current ratio is strong at 9.09, indicating good short-term financial health, but the overall trend shows increasing losses.